Moderna (MRNA:NASDAQ) Investor Relations Material

Overview

Cambridge-based biotech company Moderna, Inc. has made a name for itself in the field of messenger RNA (mRNA) therapeutics and vaccines. The company's products target a range of medical issues including infectious diseases, rare diseases, cardiovascular diseases, and immuno-oncology. Moderna's portfolio includes respiratory vaccines for ailments such as COVID-19, flu, respiratory syncytial virus, and endemics like HCoV, as well as latent vaccines for herpes simplex virus and other ailments. Additionally, the company offers systemic secreted and cell surface therapeutics, cancer vaccines, and intratumoral immuno-oncology products. Moderna has strong ties to other major pharmaceutical companies including AstraZeneca, Merck, and Vertex Pharmaceuticals. Founded in 2010 as Moderna Therapeutics, Inc., the company later changed its name to Moderna, Inc. in August 2018.

Frequently Asked Questions

What is Moderna's ticker?

Moderna's ticker is MRNA

What exchange is Moderna traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Moderna's headquarters?

They are based in Cambridge, Massachusetts

How many employees does Moderna have?

There are 501-1000 employees working at Moderna

What is Moderna's website?

It is modernatx.com

What type of sector is Moderna?

Moderna is in the Healthcare sector

What type of industry is Moderna?

Moderna is in the Biotechnology industry

Who are Moderna's peers and competitors?

The following five companies are Moderna's industry peers:

- Jazz Pharmaceuticals

- Aeglea BioTherapeutics, Inc.

- Eiger BioPharmaceuticals

- Bio-Path

- NanoString